Medical/Pharmaceuticals
111, Inc. Announces Strategic Partnership with Chugai Pharma China Co., Ltd. to Accelerate Innovations in Chronic Disease Management
SHANGHAI, Oct. 25, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced a strategic cooperation agreement with Chugai Phar...
Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer
HOUSTON and SINGAPORE, Oct. 25, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced it has entered into a clinical trial collaboration agreem...
Farrer Park Hospital Offers Transcatheter Aortic Valve Implantation (TAVI)
SINGAPORE, Oct. 25 , 2021 /PRNewswire/ -- Farrer Park Hospital ("FPH") offers TAVI as an alternative treatment option for those suffering from aortic valve stenosis who are elderly or for younger patients who are not suitable for open-heart surgery. In aortic valve stenosis, the aortic valve sit...
A Singapore-based HealthTech Startup Redefines Chronic Disease Care with Promising Clinic Acquisition
SINGAPORE, Oct. 25, 2021 /PRNewswire/ -- A HealthTech start-up, HeartVoice announced its acquisition of Integrated Wellness Clinic in Novena Specialist Center. The clinic has been offering Health Screening services for corporate clients since 2015, pioneering this field,having served over 600 cor...
NCCN Works with Polish Health Leaders to Improve Cancer Standardization, Coordination, and Outcomes
PLYMOUTH MEETING, Pa., Oct. 25, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—today announced the publication of new NCCN Guidelines® for Cervical Cancer: Poland Edition. This is the organization's most-recent co...
Meet the Next Resolution in Medicine -- Polaris Biology Releases Starion™, the next-generation mass cytometer
SHANGHAI, Oct. 23, 2021 /PRNewswire/ -- Polaris Biology, a leading innovator in
single-cell technologies, announced today the largest product launch in company
history with the introduction of the Starion™ Mass Cytometry System.
I-Mab Expands U.S. Footprint with New R&D Site in San Diego
- I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growingSan Diego biotech hub - The new site will complement I-Mab's Global Clinical Development site in Gaithersburg, Maryland to form an integrated I-Mab US R&...
Ping An Good Doctor Unveils Strategic 2.0 Continuum
SHANGHAI, Oct. 22, 2021 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor"; Stock Code: 01833.HK), the leading online medical and healthcare service platform in China, presented its business achievements and unveiled its Strategic 2.0 Continuum at an investor...
2021 Bio-enzyme Application Explorer Summit held in Chengdu
The event focuses on innovation and development of biochemical pharmaceuticals CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- The biochemical pharmaceutical industry is facing unprecedented opportunities and challenges with the changing economic and policy environment inChina and abroad. On Octobe...
Akeso is rapidly advancing the clinical study of the PD-1/CTLA-4 bispecific antibody Cadonilimab combined with TIGIT monoclonal antibody for the teratment of solid tumors
HONG KONG, Oct. 21, 2021 /PRNewswire/ -- Akeso, one of leading Chinese pharmaceutical innovation company announces that the first patient was dosed in a phase I clinical trial of the Company's independently developed TIGIT monoclonal antibody (AK127) in combination with the Company's global firs...
Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore
SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner withIncyte Biosciences International Sàrl,the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and onc...
Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China
SUZHOU, China, Oct. 21 , 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) fo...
Speclipse included in MedTech Outlook rating of top 10 non-invasive device companies
SEOUL, South Korea, Oct. 21, 2021 /PRNewswire/ -- Speclipse, a startup
specializing in laser spectroscopic and AI-based medicaldiagnostic technologies
and a member ofBorn2Global Centre, was recently included in MedTech Outlook's
"Top 10 Non InvasiveDevice Companies" ranking for 2021.
INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives
Memorandum of Understanding builds on recent regulatory authorization from INVIMAto conduct INNOVATE Phase 3 trial for INO-4800, INOVIO's COVID-19 vaccine candidate,in Colombia Colombia authorization augments recent regulatory authorizations from Brazil, the Philippines and Mexico to commence it...
Mentice's CEO Göran Malmberg to present the company's interim report at a webcast conference call on October 28 at 9:30 CEST
STOCKHOLM, Oct. 21, 2021 /PRNewswire/ -- Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFOGunilla Andersson. To register for the presentation of ...
Guangzhou Concord Cancer Center Becomes a Designated Hospital of Social Healthcare Insurance
BEIJING, Oct. 21, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone ...
Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates
SHANGHAI and HONG KONG, Oct. 21, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray
SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (''Shandong Luoxin''), a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. ("Luoxin Pharmaceutical" or "the company") , signed a licensing agreement withAustria-based Marinomed Biotech AG ("Mar...
UNO Technologies announces collaboration with Aetos Pharma to further accelerate Malaysia's healthcare tech transformation
SINGAPORE, Oct. 20, 2021 /PRNewswire/ -- UNO Technologies, a rapidly growing Medical Technology ("med tech") firm based inSingapore, has recently announced its expansion into the Malaysian market. As part of its regional strategy, UNO will team up with Aetos Pharma, a burgeoning Malaysian pharmac...
IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE
SUZHOU, China, Oct. 21, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026 (KN026-306) was official...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Multiple achievements made in China-Hungary BRI conference
[Picked up by 310 media titles]
2024-05-03 06:59Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 282 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 257 media titles]
2024-05-02 01:21